Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of Toronto
$105,000.00
Identification and in vivo characterization of pharmacological chaperones of the dopamine transporter
FY 2013-14
Summary
Our lab has previously discovered that genetically increasing a protein important in dopamine regulation, the dopamine transporter (DAT), can reduce dopamine signalling. Increasing function of DAT may be useful as a new treatment for two serious medical conditions: schizophrenia and dopamine transporter deficiency syndrome.
Schizophrenia is a mental illness affecting 0.7% of people in Canada, and is characterized by hallucinations, delusions as well as reduced emotional response and motivation. Due to the severity of the symptoms and chronic nature of this illness, schizophrenia costs an estimated CAN$ 6.85 billion annually in healthcare costs and loss of productivity. Drug treatments are available and have improved over the last ten years, but are only partially effective and have severe side-effects. Therefore, development of new drug treatments could lead to significant improvement of patient quality of life as well as reducing the economic burden on society.
Dopamine transporter deficiency syndrome is a newly discovered heritable condition that is first observed in childhood. Children suffering from this condition have a severe movement disorder that is in some ways similar to Parkinson's. These children do not survive past adolescence and currently there are no available treatments.
Although genetic regulation of DAT in humans is not currently practical, regulation of the amount of DAT with drug treatments may be a treatment approach worth investigating for these two conditions, which is the subject of our research proposal.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
307748
Name
Beerepoot Pieter
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Identification and in vivo characterization of pharmacological chaperones of the dopamine transporter
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Dopamine; Dopamine Reuptake Inhibitors; Glutamate; Membrane Proteins; Monoamine Transporters; Pharmacological Chaperones; Protein Folding; Schizophrenia; Surface Expression Assay; Transgenic Animal Models Of Mental Illness
Abstract
Our lab has previously discovered that genetically increasing a protein important in dopamine regulation, the dopamine transporter (DAT), can reduce dopamine signalling. Increasing function of DAT may be useful as a new treatment for two serious medical conditions: schizophrenia and dopamine transporter deficiency syndrome.
Schizophrenia is a mental illness affecting 0.7% of people in Canada, and is characterized by hallucinations, delusions as well as reduced emotional response and motivation. Due to the severity of the symptoms and chronic nature of this illness, schizophrenia costs an estimated CAN$ 6.85 billion annually in healthcare costs and loss of productivity. Drug treatments are available and have improved over the last ten years, but are only partially effective and have severe side-effects. Therefore, development of new drug treatments could lead to significant improvement of patient quality of life as well as reducing the economic burden on society.
Dopamine transporter deficiency syndrome is a newly discovered heritable condition that is first observed in childhood. Children suffering from this condition have a severe movement disorder that is in some ways similar to Parkinson's. These children do not survive past adolescence and currently there are no available treatments.
Although genetic regulation of DAT in humans is not currently practical, regulation of the amount of DAT with drug treatments may be a treatment approach worth investigating for these two conditions, which is the subject of our research proposal.
Competitiondate
201310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Beerepoot, Pieter
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~